BNP Paribas Asset Management
DYN icon

BNP Paribas Asset Management’s Dyne Therapeutics DYN Stock Holding History

BNP Paribas Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.99M Sell
164,887
-805
-0.5% -$13.9K ﹤0.01% 984
2025
Q4 		$3.24M Buy
165,692
+164,846
+19,485% +$3.12M ﹤0.01% 945
2025
Q3 		$11K Buy
846
+214
+34% +$2.44K ﹤0.01% 1598
2025
Q2 		$6K Buy
+632
New +$6.96K ﹤0.01% 1924

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BNP Paribas Asset Management's DYN Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Dyne Therapeutics (DYN) stake by 0.49% in Q1 2026, selling an estimated $13.9K and leaving 164,887 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #984.

BNP Paribas Asset Management first reported a position in DYN in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.24M in Q4 2025. 228 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • BNP Paribas Asset Management held 164,887 shares of Dyne Therapeutics worth $2.99M as of Q1 2026.
  • BNP Paribas Asset Management sold 805 Dyne Therapeutics shares in Q1 2026, an estimated $13.9K.
  • Dyne Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #984 holding.
  • BNP Paribas Asset Management first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Dyne Therapeutics position peaked at $3.24M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.